ROCHESTER, Minn.--(BUSINESS WIRE)--Today, Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of ...

Radiopharm Theranostics (NASDAQ:RADX) outlined progress across its radiopharmaceutical pipeline and highlighted near-term ...

Theranostics is a term derived from a combination of the words therapeutics and diagnostics. In this emerging field of medicine, drugs and/or techniques are uniquely combined to simultaneously or ...

Radiopharm Theranostics ADR (NASDAQ:RADX) is among the best Australian stocks to buy in 2026. Radiopharm Theranostics ADR ...

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier ...

GE HealthCare announced a collaboration with Grand Rapids-based cancer treatment center BAMF Health to advance the adoption of theranostics in the U.S. Theranostics is an emerging technology and a ...

Theranostics represents a broadening in the scope of personalized medicine to include companion diagnostics for health interventions ranging from drugs to vaccines, as well as individual ...

Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort Data Safety and Monitoring Committee ...

For patients with prostate cancer, theranostics may be another available treatment path to take, especially for those who need more options. For patients with prostate cancer, there are many treatment ...

Sonia Sahney needed a few extra pairs of eyes. She’d just started drafting an introductory slide on GE HealthCare’s highly personalized approach to theranostics, which taps diagnostic tools to ...

Add Yahoo as a preferred source to see more of our stories on Google. Grand Rapids-based BAMF Health is partnering with multiple Kansas City health organizations to create a state-of-the-art ...

Personalized medicine player Theranostics is in the midst of a modest fund raise – it’s raising $1 million in equity, according to a regulatory filing. Not to be confused with biotech media darling ...